Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Patent Blocks Zydus After Landmark US Approval For Dapagliflozin
AstraZeneca’s Farxiga Brand Set To Stand Until October 2025
Feb 24 2022
•
By
Dean Rudge
More than a dozen ANDA sponsors are chasing the Farxiga brand • Source: Shutterstock
More from Products
More from Generics Bulletin
